News
September 24, 2025 Research and Development
“ALAgene® technology”-Derived Antibody Therapeutic Candidate Achieves Phase I Clinical Milestone ～Driving Future Growth through Strategic License Agreement～
Pharma Foods International Co., Ltd. (Head Office: Kyoto, Japan; Representative Director: Mujo Kim; hereinafter “the Company”) announces the completion of a Phase I single dose clinical study (Registry Identifier: jRCT2031240187) of “MT-3534” by Mitsubishi Tanabe Pharma Corporation (hereinafter: “Mitsubishi Tanabe Pharma”), in July 2025.
MT-3534 is an antibody therapeutic drug candidate, co-discovered with Mitsubishi Tanabe Pharma through the Company’s proprietary antibody discovery platform, ALAgene® technology.
(PDF)